According to the WHO, AMR is among humanity's top 10 global public health threats. AMR is estimated to cause 700,000 deaths yearly, which is expected to increase to 10 million or more annually by 2050 if we do not take action.
Antimicrobial Resistance occurs when various bacteria, viruses, fungi, and some parasites develop the ability to defeat the drugs designed to kill them. This can happen due to overuse and misuse of antibiotics and poor infection control practices.
AMR can affect anyone, but it is hazardous for young and older adults, as they have weakened immune systems. It can lead to more extended hospital stays, higher medical costs, and increased mortality rates.
Venus Remedies and Cipla are two leading pharmaceutical companies in India. They have collaborated to develop and market Ceftriaxone Sulbactum EDTA in India.
The collaboration between Venus Remedies and Cipla to develop and market Ceftriaxone Sulbactum EDTA in India is a significant milestone in the battle against AMR. India is one of the countries with the highest incidence rates of AMR worldwide, and this collaboration can help to reduce the spread of AMR bacteria in the country.
The launch of Ceftriaxone Sulbactum EDTA in India will give patients access to a new, effective drug to fight AMR infections. It will also help to reduce the spread of AMR bacteria in India.
AMR can affect patients on a cellular level by making it difficult for their immune system to fight off infection.
When a person is infected with bacteria, their immune system produces white blood cells that restrict, attack, and kill the bacteria or foreign bodies. However, if the bacteria resist antibiotics, they can develop mechanisms to evade the white blood cells' attacks.
This can lead to the infection becoming more severe and prolonged. It can also make it more difficult for the patient's immune system to fight off future infections.
Ceftriaxone Sulbactum EDTA is a new drug developed to fight Antimicrobial Resistance. Elores is a life-saving drug composed of Ceftriaxone, Sulbactam, and Disodium EDTA. It is specifically designed to treat severe infections caused by gram-negative bacteria. Elores has the unique ability to maintain the effectiveness of antibiotics by using the appropriate (ARBs) Antibiotic Resistance Breakers. The product was launched in India across selected tertiary care hospitals in 2013 after approval from the Drug Controller General of India.
Combining these three antibiotics makes Ceftriaxone Sulbactum EDTA a very effective drug against AMR bacteria. The drug is also relatively safer with few side effects.
A study published in the journal "Indian Journal of Critical Care Medicine" found that Ceftriaxone Sulbactum EDTA effectively treated 95% of patients with AMR infections.
Another study, published in the journal "Clinical Microbiology and Infection," found that Ceftriaxone Sulbactum EDTA was safe and well-tolerated by patients.
These studies prove Ceftriaxone Sulbactum EDTA is a safe and effective treatment for AMR infections in India. The Venus & Cipla collaboration has played a vital role in making this drug available to patients in India and helping to fight the spread of AMR.
Ceftriaxone Sulbactum EDTA can help patients in several ways. It can:
Here are a few practices to follow to prevent AMR, including:
We all have a role to play in preventing AMR. By following the tips above, we can help to keep ourselves and our loved ones healthy.
© All Rights Reserved | Privacy Policy | Adverse Drug Reaction
The Venus & Cipla Collaboration: Tackling Antimicrobial Resistance (AMR)